1. Glipizide therapy linked to 13% increased cardiovascular events.
2. Study analyzed 48,165 adults aged 30+.
3. Median follow-up: 37 months.
4. MACE-4 includes myocardial infarction, stroke.
5. Need for personalized sulfonylurea selection emphasized.
6. DPP4 inhibitors showed lower cardiovascular risk.
7. Glyburide not linked to excess risks but has higher hypoglycemia risk.
8. Limitations include generalizability concerns.

Source: JAMA Network Open